Hexaminolevulinate
Appearance
(Redirected from Cysview)
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2019) |
![]() | This article needs more reliable medical references for verification or relies too heavily on primary sources. (April 2023) | ![]() |
![]() | |
Clinical data | |
---|---|
Trade names | Cysview, Hexvix |
License data | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) |
Hexaminolevulinate, sold under the brand name Cysview among others, is an imaging agent that lights up under blue light during a blue light cystoscopy. It is used to help detect non-muscle invasive bladder cancer (NMIBC), in particular papillary tumors and carcinoma in situ (CIS).[3]
It made by Photocure ASA, a Norwegian pharmaceutical company.
Hexaminolevulinate is a structural analogue to 5-aminolevulinic acid (a precursor to the porphyrin ring of heme), and is internalized and processed into the photoactive protoporphyrin IX at a high rate by tumor cells. After exposure to 360-450 nm light, the porphyrin will fluoresce red.[4]
References
[edit]- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Cysview- hexaminolevulinate hydrochloride kit". DailyMed. 15 November 2022. Retrieved 10 April 2023.
- ^ Zhao H, Peng P, Luo Z, Liu H, Sun J, Wang X, et al. (March 2023). "Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials". Photodiagnosis and Photodynamic Therapy. 41: 103220. doi:10.1016/j.pdpdt.2022.103220. PMID 36462704.
- ^ "Hexaminolevulinate". PubChem. U.S. National Library of Medicine.